An observational study of serum and cerebrospinal fluid concentrations of osimertinib for the treatment of lung cancer harboring EGFR activating and T790M mutations.
Latest Information Update: 09 Aug 2021
Price :
$35 *
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- 05 Aug 2021 Status changed from recruiting to completed.
- 09 Apr 2018 Status changed from not yet recruiting to recruiting.
- 18 Oct 2016 New trial record